AstraZeneca (LSE:AZN), in partnership with Daiichi Sankyo, has reported encouraging interim data from the DESTINY-Breast09 Phase III trial. The results show that Enhertu, when combined with pertuzumab, significantly enhances progression-free survival in patients with HER2-positive metastatic breast cancer, outperforming the current standa...
Continue Reading